Non-steroidal anti-inflammatory
drugs do not appear to be association with risk of squamous cell carcinoma
Contrary to previous hypotheses, the use of non-steroidal
anti-inflammatory drugs does not appear associated with risk of squamous cell
skin cancer, according to a report posted online today that will appear in the
April print issue of Archives of Dermatology, one of the JAMA/Archives journals.
Non-steroidal anti-inflammatory drugs (NSAIDs) such as
aspirin, ibuprofen and celecoxib reduce pain and inflammation by blocking an enzyme
involved in producing inflammatory compounds, according to background information
in the article. NSAIDs may also inhibit the development of cancer cells by inducing
apoptosis and inhibiting the growth of new blood vessels.
Laboratory studies of cells and animals have indicated
that NSAIDs protect against squamous cell carcinomas, common types of cancers
that appear in the upper layers of the skin. However, while some studies have
examined the associations between NSAIDs and other types of cancers-including
colorectal, breast, prostate and lung-few have assessed the association between
NSAID use and squamous cell carcinoma risk in human populations.
Maryam M. Asgari, M.D., M.P.H., of Kaiser Permanente
Northern California, Oakland, and colleagues studied 415 health plan members who
were diagnosed with squamous cell carcinoma in 2004 and 415 control patients who
were the same age, sex and race but had no history of skin cancer. Participants
completed a questionnaire about NSAID use in the 10 years prior.
The majority of participants (61 percent) reported regular
use of NSAIDs within the previous ten years, including 48 percent who used aspirin,
18 percent who used ibuprofen, 5 percent who used naproxen and 4 percent who used
nabumetone.
"Regular use of any NSAID was not associated with a reduction
in squamous cell carcinoma risk," the authors write. "Although NSAID users whose
exposure was of short duration (one to three years) appeared to be at somewhat
increased risk for squamous cell carcinoma, we found no consistent effects of
duration of use of any NSAID on squamous cell carcinoma risk." Squamous cell carcinoma
risk also did not appear to change regardless of NSAID dose, whether the medications
were administered by a pharmacy nor with any individual type of NSAID medication.
"Given the potential toxic effects of NSAIDs, including
platelet dysfunction and gastric ulcers, more uniformly efficacious chemopreventive
agents with safer adverse effect profiles need to be explored," the authors conclude.
This study was supported by grants from the National Institute of Arthritis Musculoskeletal
and Skin Diseases and from the National Cancer Institute.
|